Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium - EBCA

C2 Therapeutics, Inc.0 个研究点目标入组 15 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•a) Patient must have a minimum of 2.0 cm of non-ulcerated, non-inflammatory columnar-lined esophagus or squamous esophageal lined tissue suitable for ablation. A patient may be treated with up to 2 zones of ablation
•b) Patient is 18 to 80 years of age at the time of consent (inclusive).
•c) Patient has provided written Informed Consent Form (IFC) using a form that has been approved by the Institution*s reviewing IRB/EC.
•d) Patient is willing and able to comply with study requirements.
•e) Patient*s esophagectomy is clinically necessary due to reasons unrelated to this study.
•f) Patient is deemed operable per standard institutional criteria.

•a) Patient has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to IFC, post treatment instructions or follow-up guidelines.
•b) Patient refuses or is unable to provide written informed consent.
•c) Patient has or is currently undergoing endoscopic ablation therapy within 4 cm from the proposed treatment area including, but not limited to cryospray therapy, laser treatment, photodynamic therapy, multi-polar electro coagulation, endoscopic mucosal resection, radiofrequency ablation or argon plasma coagulation.
•d) Patient has esophageal narrowing limiting access to the intended site of ablation.
•e) Patient is undergoing or has recently undergone chemotherapy (within 15 days or WBC below normal by institutional criteria or standards).
•f) Patient is undergoing or has recently undergone radiation therapy which involved the esophagus (within 15 days or WBC below normal by institutional criteria or standards).

发起方